-
2
-
-
33646944093
-
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
-
Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006;21: 589-598.
-
(2006)
Mov Disord
, vol.21
, pp. 589-598
-
-
Tarsy, D.1
Baldessarini, R.J.2
-
3
-
-
77949525751
-
Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug
-
Li CR, Chung YC, Park TW, et al. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. World J Biol Psychiatry 2009;10: 919-924.
-
(2009)
World J Biol Psychiatry
, vol.10
, pp. 919-924
-
-
Li, C.R.1
Chung, Y.C.2
Park, T.W.3
-
4
-
-
0032731975
-
Possible tardive dystonia resulting from clozapine therapy
-
Molho ES, Factor SA. Possible tardive dystonia resulting from clozapine therapy. Mov Disord 1999;14: 873-874.
-
(1999)
Mov Disord
, vol.14
, pp. 873-874
-
-
Molho, E.S.1
Factor, S.A.2
-
5
-
-
33645293206
-
Drug Insight: from disturbed motility to disordered movement-a review of the clinical benefits and medicolegal risks of metoclopramide
-
Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement-a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006;3: 138-148.
-
(2006)
Nat Clin Pract Gastroenterol Hepatol
, vol.3
, pp. 138-148
-
-
Pasricha, P.J.1
Pehlivanov, N.2
Sugumar, A.3
Jankovic, J.4
-
6
-
-
85114484996
-
An update on tardive dyskinesia: from phenomenology to treatment
-
Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov 2013;3.
-
(2013)
Tremor Other Hyperkinet Mov
, vol.3
-
-
Waln, O.1
Jankovic, J.2
-
7
-
-
84881305397
-
Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology
-
Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013;8: 463-469.
-
(2013)
Neurology
, vol.8
, pp. 463-469
-
-
Bhidayasiri, R.1
Fahn, S.2
Weiner, W.J.3
Gronseth, G.S.4
Sullivan, K.L.5
Zesiewicz, T.A.6
-
8
-
-
0002217686
-
Neurological symptoms in pharmacotherapy of psychoses
-
Faurbye A, Rasch PJ, Petersen PB, Brandborg G, Pakkenberg H. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand 1964;40: 10-27.
-
(1964)
Acta Psychiatr Scand
, vol.40
, pp. 10-27
-
-
Faurbye, A.1
Rasch, P.J.2
Petersen, P.B.3
Brandborg, G.4
Pakkenberg, H.5
-
9
-
-
0020404121
-
Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs
-
Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982;32: 1335-1346.
-
(1982)
Neurology
, vol.32
, pp. 1335-1346
-
-
Burke, R.E.1
Fahn, S.2
Jankovic, J.3
Marsden, C.D.4
Lang, A.E.5
Gollomp, S.6
-
10
-
-
84886000640
-
Tardive dyskinesias
-
A. J. Albanese (Ed.), Chichester: Wiley-Blackwell
-
Revuelta GJ, Cloud, L, Aia PG, Factor SA. Tardive dyskinesias. In: Albanese AJ (ed.) Hyperkinetic movement disorders: differential diagnosis and treatment. Wiley-Blackwell, Chichester, 2012, pp. 331-352.
-
(2012)
Hyperkinetic Movement Disorders: Differential Diagnosis and Treatment
, pp. 331-352
-
-
Revuelta, G.J.1
Cloud, L.2
Aia, P.G.3
Factor, S.A.4
-
11
-
-
0023508569
-
Life-threatening tardive dyskinesia caused by metoclopramide
-
Samie MR, Dannenhoffer MA, Rozek S. Life-threatening tardive dyskinesia caused by metoclopramide. Mov Disord 1987;2: 125-29.
-
(1987)
Mov Disord
, vol.2
, pp. 125-129
-
-
Samie, M.R.1
Dannenhoffer, M.A.2
Rozek, S.3
-
12
-
-
21244461370
-
Neuroleptic-Induced tardive dyskinesia variants
-
S. A. Factor, A. E. Lang, and W. J. Weiner (Eds.), Malden, MA: Blackwell Futura
-
Skidmore FW, Weiner, WJ, Burke, R. Neuroleptic-Induced tardive dyskinesia variants. In: Factor SA, Lang AE, Weiner WJ (eds) Drug induced movement disorders. Blackwell Futura, Malden, MA, 2005, pp. 257-284.
-
(2005)
Drug Induced Movement Disorders
, pp. 257-284
-
-
Skidmore, F.W.1
Weiner, W.J.2
Burke, R.3
-
13
-
-
0026799190
-
Tardive dyskinesia in elderly psychiatric patients: a 5-year study
-
Yassa R, Nastase C, Dupont D, Thibeau M. Tardive dyskinesia in elderly psychiatric patients: a 5-year study. Am J Psychiatry 1992;149: 1206-1211.
-
(1992)
Am J Psychiatry
, vol.149
, pp. 1206-1211
-
-
Yassa, R.1
Nastase, C.2
Dupont, D.3
Thibeau, M.4
-
14
-
-
0029023056
-
Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients
-
Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52: 756-765.
-
(1995)
Arch Gen Psychiatry
, vol.52
, pp. 756-765
-
-
Jeste, D.V.1
Caligiuri, M.P.2
Paulsen, J.S.3
-
15
-
-
73949099769
-
Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis
-
Tenback DE, van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord 2009;24: 2309-2315.
-
(2009)
Mov Disord
, vol.24
, pp. 2309-2315
-
-
Tenback, D.E.1
van Harten, P.N.2
van Os, J.3
-
16
-
-
8744231989
-
Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center
-
Wonodi I, Adami HM, Cassady SL, Sherr JD, Avila MT, Thaker GK. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. J Clin Psychopharmacol 2004;24: 592-598.
-
(2004)
J Clin Psychopharmacol
, vol.24
, pp. 592-598
-
-
Wonodi, I.1
Adami, H.M.2
Cassady, S.L.3
Sherr, J.D.4
Avila, M.T.5
Thaker, G.K.6
-
17
-
-
0027156704
-
Diabetes and development of tardive dyskinesia
-
Woerner MG, Saltz BL, Kane JM, Lieberman JA, Alvir JM. Diabetes and development of tardive dyskinesia. Am J Psychiatry 1993;150: 966-968.
-
(1993)
Am J Psychiatry
, vol.150
, pp. 966-968
-
-
Woerner, M.G.1
Saltz, B.L.2
Kane, J.M.3
Lieberman, J.A.4
Alvir, J.M.5
-
18
-
-
0025980669
-
The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study
-
Ganzini L, Heintz RT, Hoffman WF, Casey DE. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Arch Gen Psychiatry 1991;48: 259-263.
-
(1991)
Arch Gen Psychiatry
, vol.48
, pp. 259-263
-
-
Ganzini, L.1
Heintz, R.T.2
Hoffman, W.F.3
Casey, D.E.4
-
19
-
-
0031790237
-
Prospective study of tardive dyskinesia in the elderly: rates and risk factors
-
Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998;155: 1521-1528.
-
(1998)
Am J Psychiatry
, vol.155
, pp. 1521-1528
-
-
Woerner, M.G.1
Alvir, J.M.2
Saltz, B.L.3
Lieberman, J.A.4
Kane, J.M.5
-
20
-
-
0022600929
-
Integrating incidence and prevalence of tardive dyskinesia
-
Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986;22: 254-258.
-
(1986)
Psychopharmacol Bull
, vol.22
, pp. 254-258
-
-
Kane, J.M.1
Woerner, M.2
Borenstein, M.3
Wegner, J.4
Lieberman, J.5
-
21
-
-
84891020562
-
Tardive dyskinesia
-
S. A. Factor, A. E. Lang, and W. J. Weiner (Eds.), Malden, MA: Blackwell Futura
-
Hyde TM, Apud JA, Fisher WC, Egan MF. Tardive dyskinesia. In: Factor SA, Lang AE, Weiner WJ (eds) Drug induced movement disorders. Blackwell Futura, Malden, MA, 2005, pp. 213-256.
-
(2005)
Drug Induced Movement Disorders
, pp. 213-256
-
-
Hyde, T.M.1
Apud, J.A.2
Fisher, W.C.3
Egan, M.F.4
-
22
-
-
0028856570
-
Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients
-
Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995;152: 1724-1729.
-
(1995)
Am J Psychiatry
, vol.152
, pp. 1724-1729
-
-
Chatterjee, A.1
Chakos, M.2
Koreen, A.3
-
23
-
-
0017694957
-
Spontaneous buccolinguofacial dyskinesia in the elderly
-
Delwaide PJ, Desseilles M. Spontaneous buccolinguofacial dyskinesia in the elderly. Acta Neurol Scand 1977;56: 256-262.
-
(1977)
Acta Neurol Scand
, vol.56
, pp. 256-262
-
-
Delwaide, P.J.1
Desseilles, M.2
-
24
-
-
0015364024
-
Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine
-
Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 1972;27: 95-99.
-
(1972)
Arch Gen Psychiatry
, vol.27
, pp. 95-99
-
-
Kazamatsuri, H.1
Chien, C.2
Cole, J.O.3
-
25
-
-
0015362534
-
Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate
-
Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Arch Gen Psychiatry 1972;27: 100-103.
-
(1972)
Arch Gen Psychiatry
, vol.27
, pp. 100-103
-
-
Kazamatsuri, H.1
Chien, C.2
Cole, J.O.3
-
26
-
-
33846837063
-
Tardive dyskinesia: eliminated, forgotten, or overshadowed?
-
Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 2007;20: 131-137.
-
(2007)
Curr Opin Psychiatry
, vol.20
, pp. 131-137
-
-
Remington, G.1
-
27
-
-
84893154206
-
-
Food and Drug Administration, Center for Drug Evaluation and Research
-
Kaplan S. Metoclopramide: drug use data review. memorandum. Food and Drug Administration, Center for Drug Evaluation and Research, 2005.
-
(2005)
Metoclopramide: Drug use data review
-
-
Kaplan, S.1
-
28
-
-
0020054615
-
Tardive dyskinesia: prevalence and risk factors, 1959 to 1979
-
Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39: 473-481.
-
(1982)
Arch Gen Psychiatry
, vol.39
, pp. 473-481
-
-
Kane, J.M.1
Smith, J.M.2
-
29
-
-
0026666282
-
Gender differences in tardive dyskinesia: a critical review of the literature
-
Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992;18: 701-715.
-
(1992)
Schizophr Bull
, vol.18
, pp. 701-715
-
-
Yassa, R.1
Jeste, D.V.2
-
30
-
-
0023783650
-
Tardive dyskinesia: prevalence, incidence, and risk factors
-
Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8: 52S-56S.
-
(1988)
J Clin Psychopharmacol
, vol.8
-
-
Kane, J.M.1
Woerner, M.2
Lieberman, J.3
-
31
-
-
0027264874
-
Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications
-
Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993;54: 133-139.
-
(1993)
J Clin Psychiatry
, vol.54
, pp. 133-139
-
-
Glazer, W.M.1
Morgenstern, H.2
Doucette, J.T.3
-
32
-
-
15844410325
-
Incidence and correlates of tardive dyskinesia in first episode of schizophrenia
-
Chakos MH, Alvir JM, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996;53: 313-319.
-
(1996)
Arch Gen Psychiatry
, vol.53
, pp. 313-319
-
-
Chakos, M.H.1
Alvir, J.M.2
Woerner, M.G.3
-
33
-
-
0030819935
-
The emerging role of clozapine in the treatment of movement disorders
-
Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997;12: 483-496.
-
(1997)
Mov Disord
, vol.12
, pp. 483-496
-
-
Factor, S.A.1
Friedman, J.H.2
-
34
-
-
84893033262
-
A call for caution in the use of antipsychotic drugs
-
Friedman RA. A call for caution in the use of antipsychotic drugs. New York Times, 2012.
-
(2012)
New York Times
-
-
Friedman, R.A.1
-
35
-
-
84870603148
-
National trends in the office-based treatment of children, adolescents, and adults with antipsychotics
-
Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 2012;69: 1247-1256.
-
(2012)
Arch Gen Psychiatry
, vol.69
, pp. 1247-1256
-
-
Olfson, M.1
Blanco, C.2
Liu, S.M.3
Wang, S.4
Correll, C.U.5
-
36
-
-
40349094467
-
Tardive dyskinesia and new antipsychotics
-
Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21: 151-156.
-
(2008)
Curr Opin Psychiatry
, vol.21
, pp. 151-156
-
-
Correll, C.U.1
Schenk, E.M.2
-
37
-
-
80053459019
-
Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder
-
Bakker PR, de Groot IW, van Os J, van Harten PN. Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS One 2011;6: e25588.
-
(2011)
PLoS One
, vol.6
-
-
Bakker, P.R.1
de Groot, I.W.2
van Os, J.3
van Harten, P.N.4
-
38
-
-
53949112680
-
Extrapyramidal side-effects of antipsychotics in a randomised trial
-
Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008;193: 279-288.
-
(2008)
Br J Psychiatry
, vol.193
, pp. 279-288
-
-
Miller, D.D.1
Caroff, S.N.2
Davis, S.M.3
-
39
-
-
33749321169
-
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
-
Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63: 1079-1087.
-
(2006)
Arch Gen Psychiatry
, vol.63
, pp. 1079-1087
-
-
Jones, P.B.1
Barnes, T.R.2
Davies, L.3
-
40
-
-
77951072007
-
Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study
-
Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010;71: 463-474.
-
(2010)
J Clin Psychiatry
, vol.71
, pp. 463-474
-
-
Woods, S.W.1
Morgenstern, H.2
Saksa, J.R.3
-
41
-
-
0027501805
-
Does clozapine cause tardive dyskinesia?
-
Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54: 327-330.
-
(1993)
J Clin Psychiatry
, vol.54
, pp. 327-330
-
-
Kane, J.M.1
Woerner, M.G.2
Pollack, S.3
Safferman, A.Z.4
Lieberman, J.A.5
-
42
-
-
28044470076
-
Patterns of prescription of four major antipsychotics: a retrospective study based on medical records of psychiatric inpatients
-
Gasquet I, Gury C, Tcherny-Lessenot S, Quesnot A, Gaudebout P. Patterns of prescription of four major antipsychotics: a retrospective study based on medical records of psychiatric inpatients. Pharmacoepidemiol Drug Saf 2005;14: 805-811.
-
(2005)
Pharmacoepidemiol Drug Saf
, vol.14
, pp. 805-811
-
-
Gasquet, I.1
Gury, C.2
Tcherny-Lessenot, S.3
Quesnot, A.4
Gaudebout, P.5
-
43
-
-
0024508606
-
The course of tardive dyskinesia in patients on long-term neuroleptics
-
Bergen JA, Eyland EA, Campbell JA, et al. The course of tardive dyskinesia in patients on long-term neuroleptics. Br J Psychiatry 1989;154: 523-528.
-
(1989)
Br J Psychiatry
, vol.154
, pp. 523-528
-
-
Bergen, J.A.1
Eyland, E.A.2
Campbell, J.A.3
-
44
-
-
0021904890
-
Tardive dyskinesia: reversible and irreversible
-
Casey DE. Tardive dyskinesia: reversible and irreversible. Psychopharmacology Suppl 1985;2: 88-97.
-
(1985)
Psychopharmacology Suppl
, vol.2
, pp. 88-97
-
-
Casey, D.E.1
-
45
-
-
0035957276
-
The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up
-
Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 2001;56: 805-807.
-
(2001)
Neurology
, vol.56
, pp. 805-807
-
-
Fernandez, H.H.1
Krupp, B.2
Friedman, J.H.3
-
46
-
-
0025167627
-
Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication
-
Glazer WM, Morgenstern H, Schooler N, Berkman CS, Moore DC. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry 1990;157: 585-592.
-
(1990)
Br J Psychiatry
, vol.157
, pp. 585-592
-
-
Glazer, W.M.1
Morgenstern, H.2
Schooler, N.3
Berkman, C.S.4
Moore, D.C.5
-
48
-
-
39849090320
-
Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment
-
Modestin J, Wehrli MV, Stephan PL, Agarwalla P. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment. Schizophr Res 2008;100: 97-107.
-
(2008)
Schizophr Res
, vol.100
, pp. 97-107
-
-
Modestin, J.1
Wehrli, M.V.2
Stephan, P.L.3
Agarwalla, P.4
-
49
-
-
84893052259
-
-
64th Annual Meeting of the American Academy of Neurology, 2012, New Orleans, LA. Abstract
-
Zutshi D, Cloud L, Factor S. Reversibility of tardive syndromes. 64th Annual Meeting of the American Academy of Neurology, 2012, New Orleans, LA. Abstract.
-
Reversibility of tardive syndromes
-
-
Zutshi, D.1
Cloud, L.2
Factor, S.3
-
50
-
-
0019207526
-
Changes in prevalence, severity, and recovery in tardive dyskinesia with age
-
Smith JM, Baldessarini RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980;37: 1368-1373.
-
(1980)
Arch Gen Psychiatry
, vol.37
, pp. 1368-1373
-
-
Smith, J.M.1
Baldessarini, R.J.2
-
51
-
-
0025727823
-
The prediction of chronic persistent versus intermittent tardive dyskinesia. A retrospective follow-up study
-
Glazer WM, Morgenstern H, Doucette JT. The prediction of chronic persistent versus intermittent tardive dyskinesia. A retrospective follow-up study. Br J Psychiatry 1991;158: 822-828.
-
(1991)
Br J Psychiatry
, vol.158
, pp. 822-828
-
-
Glazer, W.M.1
Morgenstern, H.2
Doucette, J.T.3
-
52
-
-
0026466790
-
A 10-year follow-up study of tardive dyskinesia
-
Yassa R, Nair NP. A 10-year follow-up study of tardive dyskinesia. Acta Psychiatr Scand 1992;86: 262-266.
-
(1992)
Acta Psychiatr Scand
, vol.86
, pp. 262-266
-
-
Yassa, R.1
Nair, N.P.2
-
53
-
-
0026454744
-
Predictors of the course of tardive dyskinesia in patients receiving neuroleptics
-
Bergen J, Kitchin R, Berry G. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics. Biol Psychiatry 1992;32: 580-594.
-
(1992)
Biol Psychiatry
, vol.32
, pp. 580-594
-
-
Bergen, J.1
Kitchin, R.2
Berry, G.3
-
55
-
-
0021165987
-
Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures
-
Gardos G, Cole JO, Rapkin RM, et al. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Arch Gen Psychiatry 1984;41: 1030-1035.
-
(1984)
Arch Gen Psychiatry
, vol.41
, pp. 1030-1035
-
-
Gardos, G.1
Cole, J.O.2
Rapkin, R.M.3
-
56
-
-
0019793974
-
Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics
-
Shenoy RS, Sadler AG, Goldberg SC, Hamer RM, Ross B. Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. J Clin Psychopharmacol 1981;1: 141-145.
-
(1981)
J Clin Psychopharmacol
, vol.1
, pp. 141-145
-
-
Shenoy, R.S.1
Sadler, A.G.2
Goldberg, S.C.3
Hamer, R.M.4
Ross, B.5
-
57
-
-
0018828867
-
Covert dyskinesia in ambulatory schizophrenia
-
Carpenter WT, Rey AG, Stephens JH. Covert dyskinesia in ambulatory schizophrenia. Lancet 1980;2: 212-213.
-
(1980)
Lancet
, vol.2
, pp. 212-213
-
-
Carpenter, W.T.1
Rey, A.G.2
Stephens, J.H.3
-
58
-
-
0019367690
-
Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia [proceedings]
-
Branchey MH, Branehey LB, Richardson MA. Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia [proceedings]. Psychopharmacol Bull 1981;17: 118-120.
-
(1981)
Psychopharmacol Bull
, vol.17
, pp. 118-120
-
-
Branchey, M.H.1
Branehey, L.B.2
Richardson, M.A.3
-
60
-
-
0028833128
-
Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study
-
Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15: 36S-44S.
-
(1995)
J Clin Psychopharmacol
, vol.15
-
-
Chouinard, G.1
-
61
-
-
0344119568
-
Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study
-
Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2003;64: 1342-1348.
-
(2003)
J Clin Psychiatry
, vol.64
, pp. 1342-1348
-
-
Bai, Y.M.1
Yu, S.C.2
Lin, C.C.3
-
62
-
-
77957857043
-
A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia
-
Chan HY, Chiang SC, Chang CJ, et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. J Clin Psychiatry 2010;71: 1226-1233.
-
(2010)
J Clin Psychiatry
, vol.71
, pp. 1226-1233
-
-
Chan, H.Y.1
Chiang, S.C.2
Chang, C.J.3
-
63
-
-
84861338422
-
Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature
-
Ono S, Suzuki Y, Shindo M, et al. Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature. J Clin Pharm Ther 2012;37: 370-372.
-
(2012)
J Clin Pharm Ther
, vol.37
, pp. 370-372
-
-
Ono, S.1
Suzuki, Y.2
Shindo, M.3
-
64
-
-
0025801091
-
The effects of clozapine on tardive dyskinesia
-
Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158: 503-510.
-
(1991)
Br J Psychiatry
, vol.158
, pp. 503-510
-
-
Lieberman, J.A.1
Saltz, B.L.2
Johns, C.A.3
Pollack, S.4
Borenstein, M.5
Kane, J.6
-
66
-
-
33645798913
-
Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial
-
Huntington Study Group
-
Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66: 366-372.
-
(2006)
Neurology
, vol.66
, pp. 366-372
-
-
-
67
-
-
0032818966
-
Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol
-
Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156: 1279-1281.
-
(1999)
Am J Psychiatry
, vol.156
, pp. 1279-1281
-
-
Ondo, W.G.1
Hanna, P.A.2
Jankovic, J.3
-
68
-
-
33847731495
-
Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
-
Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22: 193-197.
-
(2007)
Mov Disord
, vol.22
, pp. 193-197
-
-
Kenney, C.1
Hunter, C.2
Jankovic, J.3
-
69
-
-
0031029072
-
Long-term effects of tetrabenazine in hyperkinetic movement disorders
-
Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48: 358-362.
-
(1997)
Neurology
, vol.48
, pp. 358-362
-
-
Jankovic, J.1
Beach, J.2
-
70
-
-
79955609673
-
Tetrabenazine for the treatment of tardive dyskinesia
-
Leung JG, Breden EL. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother 2011;45: 525-531.
-
(2011)
Ann Pharmacother
, vol.45
, pp. 525-531
-
-
Leung, J.G.1
Breden, E.L.2
-
71
-
-
0019034630
-
Evaluation of reserpine and alpha-methyldopa in the treatment of tardive dyskinesia
-
Huang CC, Wang RI, Hasegawa A, Alverno L. Evaluation of reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacol Bull 1980;16: 41-43.
-
(1980)
Psychopharmacol Bull
, vol.16
, pp. 41-43
-
-
Huang, C.C.1
Wang, R.I.2
Hasegawa, A.3
Alverno, L.4
-
73
-
-
33645872123
-
Tetrabenazine in the treatment of hyperkinetic movement disorders
-
Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 2006;6: 7-17.
-
(2006)
Expert Rev Neurother
, vol.6
, pp. 7-17
-
-
Kenney, C.1
Jankovic, J.2
-
74
-
-
0019977930
-
Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration
-
Allen RM. Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration. Biol Psychiatry 1982;17: 719-727.
-
(1982)
Biol Psychiatry
, vol.17
, pp. 719-727
-
-
Allen, R.M.1
-
75
-
-
0015239230
-
Amantadine for dyskinesia tarda
-
Vale S, Espejel MA. Amantadine for dyskinesia tarda. N Engl J Med 1971;284: 673.
-
(1971)
N Engl J Med
, vol.284
, pp. 673
-
-
Vale, S.1
Espejel, M.A.2
-
76
-
-
0015214298
-
Amantadine hydrochloride treatment of tardive dyskinesia
-
Decker BL, Davis JM, Jonowsky DS, el-Yousef MK, Sekerke HJ. Amantadine hydrochloride treatment of tardive dyskinesia. N Engl J Med 1971;285: 860.
-
(1971)
N Engl J Med
, vol.285
, pp. 860
-
-
Decker, B.L.1
Davis, J.M.2
Jonowsky, D.S.3
El-Yousef, M.K.4
Sekerke, H.J.5
-
77
-
-
0006647256
-
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
-
Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50: 1323-1326.
-
(1998)
Neurology
, vol.50
, pp. 1323-1326
-
-
Verhagen Metman, L.1
Del Dotto, P.2
van den Munckhof, P.3
Fang, J.4
Mouradian, M.M.5
Chase, T.N.6
-
78
-
-
0345863897
-
Duration of amantadine benefit on dyskinesia of severe Parkinson's disease
-
Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75: 141-143.
-
(2004)
J Neurol Neurosurg Psychiatry
, vol.75
, pp. 141-143
-
-
Thomas, A.1
Iacono, D.2
Luciano, A.L.3
Armellino, K.4
Di Iorio, A.5
Onofrj, M.6
-
79
-
-
0033999316
-
The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study
-
Snow BJ, Macdonald L, McAuley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000;23: 82-85.
-
(2000)
Clin Neuropharmacol
, vol.23
, pp. 82-85
-
-
Snow, B.J.1
Macdonald, L.2
McAuley, D.3
Wallis, W.4
-
80
-
-
0026975680
-
Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties
-
Jackisch R, Link T, Neufang B, Koch R. Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties. Arch Int Pharmacodyn Ther 1992;320: 21-42.
-
(1992)
Arch Int Pharmacodyn Ther
, vol.320
, pp. 21-42
-
-
Jackisch, R.1
Link, T.2
Neufang, B.3
Koch, R.4
-
81
-
-
0030995082
-
A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia
-
Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1997;17: 88-91.
-
(1997)
J Clin Psychopharmacol
, vol.17
, pp. 88-91
-
-
Angus, S.1
Sugars, J.2
Boltezar, R.3
Koskewich, S.4
Schneider, N.M.5
-
82
-
-
78651415131
-
Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study
-
Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 2010;33: 271-275.
-
(2010)
Clin Neuropharmacol
, vol.33
, pp. 271-275
-
-
Pappa, S.1
Tsouli, S.2
Apostolou, G.3
Mavreas, V.4
Konitsiotis, S.5
-
83
-
-
44849130867
-
Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study
-
Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2008;69: 546-554.
-
(2008)
J Clin Psychiatry
, vol.69
, pp. 546-554
-
-
Woods, S.W.1
Saksa, J.R.2
Baker, C.B.3
Cohen, S.J.4
Tek, C.5
-
84
-
-
0041623023
-
Levetiracetam as a treatment for tardive dyskinesia: a case report
-
McGavin CL, John V, Musser WS. Levetiracetam as a treatment for tardive dyskinesia: a case report. Neurology 2003;61: 419.
-
(2003)
Neurology
, vol.61
, pp. 419
-
-
McGavin, C.L.1
John, V.2
Musser, W.S.3
-
85
-
-
33646700970
-
Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series
-
Bona JR. Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series. J Clin Psychopharmacol 2006;26: 215-216.
-
(2006)
J Clin Psychopharmacol
, vol.26
, pp. 215-216
-
-
Bona, J.R.1
-
86
-
-
33748346041
-
Levetiracetam in tardive dyskinesia: an open label study
-
Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord 2006;21: 1219-1221.
-
(2006)
Mov Disord
, vol.21
, pp. 1219-1221
-
-
Konitsiotis, S.1
Pappa, S.2
Mantas, C.3
Mavreas, V.4
-
87
-
-
33748975749
-
Levetiracetam in tardive dyskinesia
-
Meco G, Fabrizio E, Epifanio A, Morgante F, Valente M, Vanacore N, et al. Levetiracetam in tardive dyskinesia. Clin Neuropharmacol 2006;29: 265-268.
-
(2006)
Clin Neuropharmacol
, vol.29
, pp. 265-268
-
-
Meco, G.1
Fabrizio, E.2
Epifanio, A.3
Morgante, F.4
Valente, M.5
Vanacore, N.6
-
88
-
-
78651241450
-
Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial
-
Wolz M, Lohle M, Strecker K, et al. Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial. J Neural Transm 2010;117: 1279-1286.
-
(2010)
J Neural Transm
, vol.117
, pp. 1279-1286
-
-
Wolz, M.1
Lohle, M.2
Strecker, K.3
-
89
-
-
0019949908
-
Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs
-
Kabes J, Sikora J, Pisvejc J, Hanzlicek L, Skondia V. Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs. Int Pharmacopsychiatry 1982;17: 185-192.
-
(1982)
Int Pharmacopsychiatry
, vol.17
, pp. 185-192
-
-
Kabes, J.1
Sikora, J.2
Pisvejc, J.3
Hanzlicek, L.4
Skondia, V.5
-
90
-
-
34548316587
-
Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study
-
Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2007;68: 1031-1037.
-
(2007)
J Clin Psychiatry
, vol.68
, pp. 1031-1037
-
-
Libov, I.1
Miodownik, C.2
Bersudsky, Y.3
Dwolatzky, T.4
Lerner, V.5
-
91
-
-
0025264442
-
Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy
-
Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 1990;147: 445-451.
-
(1990)
Am J Psychiatry
, vol.147
, pp. 445-451
-
-
Thaker, G.K.1
Nguyen, J.A.2
Strauss, M.E.3
Jacobson, R.4
Kaup, B.A.5
Tamminga, C.A.6
-
92
-
-
84870318173
-
Propranolol therapy for tardive dyskinesia revisited
-
Factor SA. Propranolol therapy for tardive dyskinesia revisited. Mov Disord 2012;27: 1703.
-
(2012)
Mov Disord
, vol.27
, pp. 1703
-
-
Factor, S.A.1
-
93
-
-
0018901839
-
Low-dose propranolol in tardive dyskinesia
-
Bacher NM, Lewis HA. Low-dose propranolol in tardive dyskinesia. Am J Psychiatry 1980;137: 495-497.
-
(1980)
Am J Psychiatry
, vol.137
, pp. 495-497
-
-
Bacher, N.M.1
Lewis, H.A.2
-
94
-
-
0020598144
-
Propranolol in the treatment of tardive-dyskinesia
-
Perenyi A, Farkas A. Propranolol in the treatment of tardive-dyskinesia. Biol Psychiatry 1983;18: 391-394.
-
(1983)
Biol Psychiatry
, vol.18
, pp. 391-394
-
-
Perenyi, A.1
Farkas, A.2
-
95
-
-
0019991653
-
Treatment of tardive-dyskinesia with propranolol
-
Schrodt GR, Wright JH, Simpson R, Moore DP, Chase S. Treatment of tardive-dyskinesia with propranolol. J Clin Psychiatry 1982;43: 328-331.
-
(1982)
J Clin Psychiatry
, vol.43
, pp. 328-331
-
-
Schrodt, G.R.1
Wright, J.H.2
Simpson, R.3
Moore, D.P.4
Chase, S.5
-
98
-
-
0033428455
-
Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study
-
Lerner V, Kaptsan A, Miodownik C, Kotler M. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study. Clin Neuropharmacol 1999;22: 241-243.
-
(1999)
Clin Neuropharmacol
, vol.22
, pp. 241-243
-
-
Lerner, V.1
Kaptsan, A.2
Miodownik, C.3
Kotler, M.4
-
99
-
-
37049021960
-
Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study
-
Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry 2007;68: 1648-1654.
-
(2007)
J Clin Psychiatry
, vol.68
, pp. 1648-1654
-
-
Lerner, V.1
Miodownik, C.2
Kaptsan, A.3
-
100
-
-
79959266946
-
Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial
-
Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72: 615-621.
-
(2011)
J Clin Psychiatry
, vol.72
, pp. 615-621
-
-
Zhang, W.F.1
Tan, Y.L.2
Zhang, X.Y.3
Chan, R.C.4
Wu, H.R.5
Zhou, D.F.6
-
102
-
-
1442284529
-
Branched chain amino acid treatment of tardive dyskinesia in children and adolescents
-
Richardson MA, Small AM, Read LL, Chao HM, Clelland JD. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J Clin Psychiatry 2004;65: 92-96.
-
(2004)
J Clin Psychiatry
, vol.65
, pp. 92-96
-
-
Richardson, M.A.1
Small, A.M.2
Read, L.L.3
Chao, H.M.4
Clelland, J.D.5
-
103
-
-
0038149630
-
Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men
-
Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry 2003;160: 1117-1124.
-
(2003)
Am J Psychiatry
, vol.160
, pp. 1117-1124
-
-
Richardson, M.A.1
Bevans, M.L.2
Read, L.L.3
-
104
-
-
77954953999
-
Lingual protrusion dystonia: frequency etiology and botulinum toxin therapy
-
Esper CD, Freeman A, Factor SA. Lingual protrusion dystonia: frequency etiology and botulinum toxin therapy. Park Rel Disord 2010;16: 438-441.
-
(2010)
Park Rel Disord
, vol.16
, pp. 438-441
-
-
Esper, C.D.1
Freeman, A.2
Factor, S.A.3
-
106
-
-
49849086653
-
Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature
-
Hennings JM, Krause E, Botzel K, Wetter TC. Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 2008;32: 1167-1171.
-
(2008)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.32
, pp. 1167-1171
-
-
Hennings, J.M.1
Krause, E.2
Botzel, K.3
Wetter, T.C.4
-
108
-
-
61849163780
-
A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation
-
Kefalopoulou Z, Paschali A, Markaki E, Vassilakos P, Ellul J, Constantoyannis C. A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation. Acta Neurol Scand 2009;119: 269-273.
-
(2009)
Acta Neurol Scand
, vol.119
, pp. 269-273
-
-
Kefalopoulou, Z.1
Paschali, A.2
Markaki, E.3
Vassilakos, P.4
Ellul, J.5
Constantoyannis, C.6
-
109
-
-
33846855983
-
Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia
-
Damier P, Thobois S, Witjas T, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry 2007;64: 170-176.
-
(2007)
Arch Gen Psychiatry
, vol.64
, pp. 170-176
-
-
Damier, P.1
Thobois, S.2
Witjas, T.3
-
110
-
-
4544307741
-
Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia
-
Schrader C, Peschel T, Petermeyer M, Dengler R, Hellwig D. Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia. Mov Disord 2004;19: 583-585.
-
(2004)
Mov Disord
, vol.19
, pp. 583-585
-
-
Schrader, C.1
Peschel, T.2
Petermeyer, M.3
Dengler, R.4
Hellwig, D.5
-
111
-
-
33744486879
-
Deep brain stimulation in the treatment of tardive dystonia
-
Zhang JG, Zhang K, Wang ZC. Deep brain stimulation in the treatment of tardive dystonia. Chin Med J (Engl) 2006;119: 789-792.
-
(2006)
Chin Med J (Engl)
, vol.119
, pp. 789-792
-
-
Zhang, J.G.1
Zhang, K.2
Wang, Z.C.3
-
112
-
-
0021846840
-
Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale
-
Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SI. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis 1985;173: 353-357.
-
(1985)
J Nerv Ment Dis
, vol.173
, pp. 353-357
-
-
Lane, R.D.1
Glazer, W.M.2
Hansen, T.E.3
Berman, W.H.4
Kramer, S.I.5
-
113
-
-
0027534918
-
The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity
-
Gerlach J, Korsgaard S, Clemmesen P, et al. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand 1993;87: 244-252.
-
(1993)
Acta Psychiatr Scand
, vol.87
, pp. 244-252
-
-
Gerlach, J.1
Korsgaard, S.2
Clemmesen, P.3
-
114
-
-
0022932306
-
Natural history and treatment of tardive dystonia
-
Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986;1: 193-208.
-
(1986)
Mov Disord
, vol.1
, pp. 193-208
-
-
Kang, U.J.1
Burke, R.E.2
Fahn, S.3
-
115
-
-
84866601685
-
Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba
-
Zhang XY, Zhang WF, Zhou DF, et al. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol Psychiatry 2012;72: 700-706.
-
(2012)
Biol Psychiatry
, vol.72
, pp. 700-706
-
-
Zhang, X.Y.1
Zhang, W.F.2
Zhou, D.F.3
-
116
-
-
0034061290
-
Tardive dyskinesia: pathophysiology and animal models
-
Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 2000;61(Suppl.4: 5-9.
-
(2000)
J Clin Psychiatry
, vol.61
, Issue.SUPPL. 4
, pp. 5-9
-
-
Casey, D.E.1
-
117
-
-
31544451267
-
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction
-
Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 2005;50: 541-547.
-
(2005)
Can J Psychiatry
, vol.50
, pp. 541-547
-
-
Margolese, H.C.1
Chouinard, G.2
Kolivakis, T.T.3
Beauclair, L.4
Miller, R.5
|